porcine brain-derived peptide preparation (cerebrolysin) Report issue

Small molecule Experimental
AACT MeSH

Active Ingredient History

NOW
  • Now
Cerebrolysin is a mixture of enzymatically treated peptides derived from pig brain whose constituents can include brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF).   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Alternative names

cerebrolysin | cerebrolysine | fpf1070 | fpf 1070

Organizations (20)

Research & Development (20)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (17)

Approved Indications (1)


 

Brain

Experimental Indications - Clinical Trial Phases 1-4 (16)


 

Alzheimer Disease (Phase 2)

Brain Injuries, Traumatic (Phase 4)

Brain Ischemia (Phase 2/Phase 3)

Cerebral Palsy (Phase 1)

Child Development (Phase 1)

Consciousness Disorders (Phase 4)

COVID-19 (Phase 4)

Deficiency Diseases (Phase 2/Phase 3)

Down Syndrome (Phase 2)

Drugs, Investigational (Phase 4)

Hypoxia-Ischemia, Brain (Phase 2)

Infant, Premature (Phase 1)

Intracranial Aneurysm (Phase 2/Phase 3)

Ischemic Stroke (Phase 4)

Stroke (Phase 4)

Subarachnoid Hemorrhage (Phase 2/Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 14
  • # of Trial Organizations: 20

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue